Literature DB >> 33447909

Recent Advancement in Nanotechnology-Based Drug Delivery System Against Viral Infections.

Deepak Pradhan1, Prativa Biswasroy1, Amit Goyal2, Goutam Ghosh1, Goutam Rath3.   

Abstract

In the last few decades, the exponential rise in the incidence of viral infections sets a global health emergency across the world. The biomimetic architecture, the ability to hijack host immune responses, continuous antigen shifting, and drafting are the major critical factors that are responsible for the unavailability of a concrete therapeutic regimen against viral infections. Further, inappropriate pharmacodynamic physicochemical and biological parameters such as low aqueous solubility, poor permeability, high affinity for plasm proteins, short biological half-lives, and fast elimination from the systemic circulation are the major critical factors that govern the suboptimal drug concentration at the target site that leads to the development of drug resistance. To address this issue, nanotechnology-based drug delivery approach is emerged as an altering method to attain the optimal drug concentration at the target site for a prolonged period by integrating the nanoengineering tools in the synthesis of nanoparticles. Nanodimensional configuration with enhanced permeability and retention effect, increased surface-area-to-volume ratio, provision for surface functionalization, etc., are the privileged aspects that make it an effective drug delivery system for dispensing the antiviral therapeutics. However, size, shape, charge, and surface topology of nanoparticles are the greater influential factors that determine target-specific drug delivery, optimum cellular uptake, degree of opsonization by the host immune cells, drug retention time, transcytosis, the extension of biological half-life, in vivo stability, and cytotoxicity. The review will enlighten the elaborative role of nanotechnology-based drug delivery and the major challenging aspect of clinical safety and efficacy.

Entities:  

Keywords:  antiviral; organic and inorganic nanocarrier system; pharmacokinetics; targeted delivery; therapeutic nanoparticles

Year:  2021        PMID: 33447909     DOI: 10.1208/s12249-020-01908-5

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  69 in total

Review 1.  Antiviral treatment for chronic hepatitis B in renal transplant patients.

Authors:  Ezequiel Ridruejo
Journal:  World J Hepatol       Date:  2015-02-27

2.  Daily dosing of highly active antiretroviral therapy.

Authors:  Keith A Rosenbach; Robert Allison; Jeffrey P Nadler
Journal:  Clin Infect Dis       Date:  2002-01-25       Impact factor: 9.079

3.  Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability.

Authors:  C Marzolini; T Buclin; L A Decosterd; J Biollaz; A Telenti
Journal:  Ther Drug Monit       Date:  2001-08       Impact factor: 3.681

Review 4.  Adverse effects of antiretroviral therapy for HIV infection.

Authors:  Valentina Montessori; Natasha Press; Marianne Harris; Linda Akagi; Julio S G Montaner
Journal:  CMAJ       Date:  2004-01-20       Impact factor: 8.262

Review 5.  A review of the pharmacokinetics of abacavir.

Authors:  Geoffrey J Yuen; Steve Weller; Gary E Pakes
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

6.  Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.

Authors:  Jeffrey P Nadler; Joseph C Gathe; Richard B Pollard; Gary J Richmond; Qiming Liao; Sandy Griffith; C Tracey Lancaster; Jaime E Hernandez; Keith A Pappa
Journal:  BMC Infect Dis       Date:  2003-06-10       Impact factor: 3.090

7.  Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance.

Authors:  Guiliang Wang; Yan Liu; Ping Qiu; Shu-Feng Zhou; Linfang Xu; Ping Wen; Jianbo Wen; Xianzhong Xiao
Journal:  Drug Des Devel Ther       Date:  2015-06-02       Impact factor: 4.162

Review 8.  Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability.

Authors:  Iris Usach; Virginia Melis; José-Esteban Peris
Journal:  J Int AIDS Soc       Date:  2013-09-04       Impact factor: 5.396

9.  Pediatric Dosing of Ganciclovir and Valganciclovir: How Model-Based Simulations Can Prevent Underexposure and Potential Treatment Failure.

Authors:  Karin Jorga; Bruno Reigner; Clarisse Chavanne; Giuseppe Alvaro; Nicolas Frey
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-12-18

10.  Fighting viruses with antibiotics: an overlooked path.

Authors:  Philippe Colson; Didier Raoult
Journal:  Int J Antimicrob Agents       Date:  2016-08-05       Impact factor: 5.283

View more
  3 in total

1.  Highly active antiretroviral therapy conjugated silver nanoparticle ameliorates testicular injury in type-2 diabetic rats.

Authors:  Samuel Oluwaseun Olojede; Sodiq Kolawole Lawal; Ayobami Dare; Roshila Moodley; Carmen Olivia Rennie; Edwin C S Naidu; Onyemaechi Okpara Azu
Journal:  Heliyon       Date:  2021-12-09

2.  Hydrotalcite-Niclosamide Nanohybrid as Oral Formulation towards SARS-CoV-2 Viral Infections.

Authors:  Goeun Choi; Huiyan Piao; N Sanoj Rejinold; Seungjin Yu; Ki-Yeok Kim; Geun-Woo Jin; Jin-Ho Choy
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-19

Review 3.  Revolutionizing polymer-based nanoparticle-linked vaccines for targeting respiratory viruses: A perspective.

Authors:  Yinghan Chan; Sin Wi Ng; Sachin Kumar Singh; Monica Gulati; Gaurav Gupta; Sushil Kumar Chaudhary; Goh Bey Hing; Trudi Collet; Ronan MacLoughlin; Raimar Löbenberg; Brian G Oliver; Dinesh Kumar Chellappan; Kamal Dua
Journal:  Life Sci       Date:  2021-06-24       Impact factor: 6.780

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.